schizophrenia, Bristol Myers Squibb
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
4d
Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback